- Home
- IGMS vs SHLS Comparison
IGMS vs SHLS Comparison
Compare IGMS & SHLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- SHLS
- Stock Information
- Founded
- IGMS 1993
- SHLS 1996
- Country
- IGMS United States
- SHLS United States
- Employees
- IGMS N/A
- SHLS N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- SHLS Semiconductors
- Sector
- IGMS Health Care
- SHLS Technology
- Exchange
- IGMS Nasdaq
- SHLS Nasdaq
- Market Cap
- IGMS 962.1M
- SHLS 951.6M
- IPO Year
- IGMS 2019
- SHLS 2021
- Fundamental
- Price
- IGMS $9.47
- SHLS $4.56
- Analyst Decision
- IGMS Hold
- SHLS Buy
- Analyst Count
- IGMS 8
- SHLS 18
- Target Price
- IGMS $14.63
- SHLS $12.14
- AVG Volume (30 Days)
- IGMS 238.9K
- SHLS 5.3M
- Earning Date
- IGMS 11-08-2024
- SHLS 11-12-2024
- Dividend Yield
- IGMS N/A
- SHLS N/A
- EPS Growth
- IGMS N/A
- SHLS N/A
- EPS
- IGMS N/A
- SHLS 0.19
- Revenue
- IGMS $2,918,000.00
- SHLS $422,657,000.00
- Revenue This Year
- IGMS $298.54
- SHLS N/A
- Revenue Next Year
- IGMS N/A
- SHLS $17.85
- P/E Ratio
- IGMS N/A
- SHLS $23.49
- Revenue Growth
- IGMS 57.64
- SHLS N/A
- 52 Week Low
- IGMS $4.72
- SHLS $4.53
- 52 Week High
- IGMS $22.50
- SHLS $17.50
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- SHLS 37.00
- Support Level
- IGMS $10.91
- SHLS $4.64
- Resistance Level
- IGMS $16.32
- SHLS $5.36
- Average True Range (ATR)
- IGMS 1.53
- SHLS 0.44
- MACD
- IGMS -0.79
- SHLS -0.08
- Stochastic Oscillator
- IGMS 0.80
- SHLS 1.82
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About SHLS Shoals Technologies Group Inc.
Shoals Technologies Group is a provider of electrical balance of system solutions for solar energy projects, primarily in the United States. EBOS encompasses components that are necessary to carry electric current produced by solar panels to an inverter. The products are sold principally to engineering, procurement, and construction firms that build solar energy projects.